Stock Surges to Highs: Social media buzz centers on Natera's recent climb to fresh 52-week highs, with the shares trading near $340 after testing key moving averages. Observers highlight the stock's 80 percent gain since a recent support level, attributing momentum to broader healthcare sector strength.
Institutional Backing Noted: Discussions also reference major fund positions in the genetic testing firm, including a leading stake from Duquesne Capital as of mid-year. Participants point to solid revenue growth and improving margins from the latest quarterly update as factors sustaining interest.
Caution on Momentum: While the tone remains upbeat on the company's trajectory, some voices advise against chasing the current levels and suggest watching for pullbacks to reenter. Overall sentiment stays bullish amid the sector's outperformance.
Note: This discussion summary was generated from an AI condensation of post data.
Natera Insider Trading Activity
Natera insiders have traded $NTRA stock on the open market 264 times in the past 6 months. Of those trades, 0 have been purchases and 264 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 53 sales selling 313,157 shares for an estimated $62,938,123.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 33 sales selling 73,355 shares for an estimated $17,762,965.
- ROELOF BOTHA has made 0 purchases and 6 sales selling 78,000 shares for an estimated $17,184,092.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 30 sales selling 66,283 shares for an estimated $14,704,918.
- JONATHAN SHEENA has made 0 purchases and 75 sales selling 42,606 shares for an estimated $10,765,227.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 33 sales selling 25,778 shares for an estimated $5,815,846.
- HERM ROSENMAN sold 16,530 shares for an estimated $4,132,500
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 9 sales selling 12,649 shares for an estimated $3,455,226.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 17 sales selling 12,502 shares for an estimated $2,826,537.
- GAIL BOXER MARCUS has made 0 purchases and 4 sales selling 11,000 shares for an estimated $2,389,328.
- ROWAN E CHAPMAN has made 0 purchases and 3 sales selling 3,221 shares for an estimated $702,984.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Natera Revenue
Natera had revenues of $752.8M in Q2 2026. This is an increase of 37.71% from the same period in the prior year.
You can track NTRA financials on Quiver Quantitative's NTRA stock page.
You can access data on NTRA stock through the Quiver Quantitative API.
Natera Hedge Fund Activity
We have seen 502 institutional investors add shares of Natera stock to their portfolio, and 367 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 12,865,346 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,492,298,171
- PRICE T ROWE ASSOCIATES INC /MD/ removed 3,162,981 shares (-26.0%) from their portfolio in Q2 2026, for an estimated $858,591,192
- FMR LLC added 2,897,142 shares (+113.4%) to their portfolio in Q2 2026, for an estimated $786,429,195
- GOLDMAN SACHS GROUP INC added 952,921 shares (+124.2%) to their portfolio in Q2 2026, for an estimated $258,670,405
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 806,536 shares (+inf%) to their portfolio in Q2 2026, for an estimated $218,934,197
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 795,962 shares (+242.8%) to their portfolio in Q2 2026, for an estimated $216,063,884
- WELLINGTON MANAGEMENT GROUP LLP removed 727,855 shares (-15.3%) from their portfolio in Q2 2026, for an estimated $197,576,239
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Natera Government Contracts
We have seen $552,900 of award payments to $NTRA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $154,100
- NEXT GENERATION SEQUENCING AND PERIPHERAL BLOOD CTDNA TESTING SERVICES (RESEARCH): $7,000
- GENETIC TESTING: $3,300
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Natera Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 06/23/2026
- William Blair issued a "Outperform" rating on 04/14/2026
To track analyst ratings and price targets for Natera, check out Quiver Quantitative's $NTRA forecast page.
Natera Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 11 analysts offer price targets for $NTRA in the last 6 months, with a median target of $275.0.
Here are some recent targets:
- Tejas Savant from Morgan Stanley set a target price of $310.0 on 07/09/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $300.0 on 07/06/2026
- Subbu Nambi from Guggenheim set a target price of $290.0 on 06/29/2026
- Eve Burstein from Bernstein set a target price of $310.0 on 06/26/2026
- Luke Sergott from Barclays set a target price of $260.0 on 06/24/2026
- Mark Massaro from BTIG set a target price of $275.0 on 06/24/2026
- Dan Leonard from RBC Capital set a target price of $275.0 on 06/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
